Sarepta Therapeutics (MEX:SRPT) Other Current Receivables: MXN2,761 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
36 GF Score
Price MXN294.00
GF Value MXN2,429.54
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Other Current Receivables?

Sarepta Therapeutics MEX:SRPT 36 Other Current Receivables is MXN2,761 Mil as of Mar. 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN2,429.54 (Possible Value Trap). The stock has 5 warning signs investors should review.

Sarepta Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was MXN2,761 Mil.

Sarepta Therapeutics's quarterly Other Current Receivables declined from Sep. 2025 (MXN2,675.78 Mil) to Dec. 2025 (MXN2,185.48 Mil) but then increased from Dec. 2025 (MXN2,185.48 Mil) to Mar. 2026 (MXN2,760.72 Mil).

Sarepta Therapeutics's annual Other Current Receivables increased from Dec. 2023 (MXN622.07 Mil) to Dec. 2024 (MXN1,036.74 Mil) and increased from Dec. 2024 (MXN1,036.74 Mil) to Dec. 2025 (MXN2,185.48 Mil).

Sarepta Therapeutics Other Current Receivables Related Terms

Sarepta Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Other Current Receivables Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 405.25 915.77 622.07 1,036.74 2,185.48

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,332.91 1,549.64 2,675.78 2,185.48 2,760.72
MEX:SRPT
36GF Score
Sarepta Therapeutics Inc MEX:SRPT
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of MXN2,761 Mil mean?
Sarepta Therapeutics (MEX:SRPT) has a Other Current Receivables of MXN2,761 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Other Current Receivables too high?
Sarepta Therapeutics' current Other Current Receivables is MXN2,761 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Other Current Receivables compare to ZYME and BCAX?
Sarepta Therapeutics' Other Current Receivables of MXN2,761 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Other Current Receivables is MXN2,761 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,429.54, compared to a current price of MXN294.00 — trading 87.9% below its estimated fair value. The current Other Current Receivables is MXN2,761 Mil. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Other Current Receivables is MXN2,761 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN294.00 is trading 87.9% below its estimated GF Value™ of MXN2,429.54. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Other Current Receivables: MXN2,761 Mil
  • GF Value™: MXN2,429.54 vs. price of MXN294.00 (87.9% below fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score

Get the complete analysis for MEX:SRPT

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN294.00
Price
MXN2,429.54
GF Value